News reports about diabetes and weight-loss medicines causing vision loss can be frightening. Here is what patients should know.
What is NAION?
Non-arteritic anterior ischemic optic neuropathy, or NAION, occurs when blood flow to part of the optic nerve is reduced. It can cause sudden, usually painless vision loss in one eye. The damage may be permanent.
Which medicines are involved?
The strongest safety concern involves semaglutide, the medicine in Ozempic, Rybelsus, and Wegovy. The findings should not automatically be applied equally to every GLP-1 medicine.
European regulators classify NAION as a very rare side effect of semaglutide. Their review estimated approximately one additional case per 10,000 people treated for one year. Research findings vary, and the precise risk remains under study.
Should I stop my medicine?
Do not stop treatment solely because of a news report. Discuss your individual benefits and risks with your clinician, especially if you have previously had NAION.
Which symptoms need immediate attention?
Sudden vision loss, a new dark area in your vision, or rapidly worsening eyesight requires immediate medical evaluation—even if there is no pain. Contact an eye specialist immediately or go to an emergency department. Do not wait for your next appointment.
If NAION is confirmed, European guidance recommends stopping semaglutide under medical supervision.
What does the research mean for you?
Some studies suggest that semaglutide—the medicine in Ozempic, Rybelsus, and Wegovy—may slightly increase the risk of NAION, a rare condition affecting blood flow to the optic nerve. The overall risk remains low. Studies have not conclusively proven that the medicine causes this condition.
If you develop sudden vision loss, seek immediate evaluation by an ophthalmologist. Do not wait for your next appointment.
Whether to start, continue, or stop treatment should be decided with your prescribing clinician and eye specialist. Together, you can weigh the medicine’s benefits against your individual eye risks, especially if you have previously had NAION or receive a new diagnosis. The American Academy of ophthalmology.
